Pathogenetic and clinical correlation of type 2 diabetes mellitus with metabolic syndrome and chronic coronary artery disease

Main Article Content

R.Ya. Dutka
N.V. Chmyr


Background. Increase of morbidity of diabetes mellitus (DM) associated with coronary artery disease (CAD) on the background of metabolic syndrome (MS) is worrisome. It is very important to improve the diagnosis of this associated pathology and also to develop pathogenetic therapy, taking into account the specific stage of disease. The purpose of our work was to study the correlation of compensated and decompensated type 2 DM on the background of MS with chronic CAD. Materials and methods. 231 patients with MS and with or without type 2 DM and chronic CAD were examined. MS was characterized by the II–IIІ degree of obesity in all studied groups. The levels of cortisol, prolactin, free thyroxine, thyroid­stimulating hormone (TSH), lipids were evaluated in all patients, ultrasonography of the heart was performed. Results. Increase of cortisol levels, prolactin in women, TSH, change of lipids as high levels of triglycerides, very low­density lipoprotein cholesterol, at the control value of high­density lipoprotein cholesterol, low­density lipoprotein cholesterol and total cholesterol was detected in patients with metabolic syndrome, and also patients with compensated type 2 DM on the background of MS. Increase of interventricular septal thickness and left atrium anteroposterior dimension was observed in patients of this group. Increased levels of cortisol and prolactin as well as the control level of TSH were detected in patients with MS and decompensated type 2 DM as well as with or without chronic CAD. Increase of interventricular septal thickness, left ventricular posterior wall thickness, left atrium anteroposterior dimension was observed in patients of both groups according to results of ultrasonography. High level of total cholesterol, low­density lipoprotein cholesterol, triglycerides, very low­density lipoprotein cholesterol and low level of high­density lipoprotein cholesterol were observed in patients with MS and decompensated type 2 DM associated with chronic CAD compared to patients with MS and type 2 DM without chronic CAD. Conclusions. The pathogenetic and clinical relation of type 2 DM was established in MS and chronic CAD.

Article Details

How to Cite
Dutka, R., and N. Chmyr. “Pathogenetic and Clinical Correlation of Type 2 Diabetes Mellitus With Metabolic Syndrome and Chronic Coronary Artery Disease”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 14, no. 7, Dec. 2018, pp. 655-60, doi:10.22141/2224-0721.14.7.2018.148772.
Original Researches


Smilowitz NR, Gupta N, Guo Y, Beckman JA, Bangalore S, Berger JS. Trends in cardiovascular risk factor and disease prevalence in patients undergoing non-cardiac surgery. Heart. 2018 Jul;104(14):1180-1186. doi: 10.1136/heartjnl-2017-312391.

van Herpt W, Dehghan A, Hoek M, et al. The clinical value of metabolic syndrome and risks of cardiometabolic events and mortality in the elderly: the Rotterdam study. Cardiovasc Diabetol. 2016 Apr 27;15:69. doi: 10.1186/s12933-016-0387-4.

De Santis AS, Diez Roux AV, Hajat A, et al. Associations of Salivary Cortisol Levels with Metabolic Syndrome and Its Components: The Multi-Ethnic Study of Atherosclerosis. J Clin Endocrinol Metab. 2011 Nov;96(11):3483-92. doi: 10.1210/jc.2011-0483.

Incollingo Rodriguez AC, Epel ES, White ML, Standen EC, Seckl JR, Tomiyama AJ. Hypothalamic-pituitary-adrenal axis dysregulation and cortisol activity in obesity: a systematic review. Psychoneuroendocrinology. 2015 Dec;62:301-18. doi: 10.1016/j.psyneuen.2015.08.014.

Tchernof A, Després JP. Pathophysiology of Human Visceral Obesity: An Update. Physiol Rev. 2013 Jan;93(1):359-404. doi: 10.1152/physrev.00033.2011.

Mc Cracken E, Monaghan M, Sreenivasan S. Pathophysiology of the metabolic syndrome. Clin Dermatol. 2018 Jan - Feb;36(1):14-20. doi: 10.1016/j.clindermatol.2017.09.004.

Montazerifar F, Bolouri AA, Mahmoudi Mozaffar M, Karajibani M. The Prevalence of Metabolic Syndrome in Coronary Artery Disease Patients. Cardiol Res. 2016 Dec;7(6):202-208. doi: 10.14740/cr507w.

Mahbuba S, Mohsin F, Rahat F, Nahar J, Begum T, Nahar N. Descriptive epidemiology of metabolic syndrome among obese adolescent population. Diabetes Metab Syndr. 2018 May;12(3):369-374. doi: 10.1016/j.dsx.2017.12.026.

Marott SC, Nordestgaard BG, Tybjærg-Hansen A, Benn M. Components of the metabolic syndrome and risk of type 2 diabetes. J Clin Endocrinol Metab. 2016 Aug;101(8):3212-21. doi: 10.1210/jc.2015-3777.

Gundogan K, Bayram F, Gedik V, et al. Metabolic syndrome prevalence according to ATP III and IDF criteria and related factors in Turkish adults. Arch Med Sci. 2013 Apr 20;9(2):243-53. doi: 10.5114/aoms.2013.34560.

Hinnouho GM, Czernichow S, Dugravot A, et al. Metabolically healthy obesity and the risk of cardiovascular disease and type 2 diabetes: the Whitehall II cohortstudy. Eur Heart J. 2015 Mar 1;36(9):551-9. doi: 10.1093/eurheartj/ehu123.

Wang T, Xu Y, Xu M et al. Circulating prolactin and risk of type 2 diabetes: a prospective study. Diabetes Care. 2013 Jul;36(7):1974-80. doi: 10.2337/dc12-1893.

van Vliet-Ostaptchouk JV, Nuotio ML, Slagter SN, et al. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocr Disord. 2014 Feb 1;14:9. doi: 10.1186/1472-6823-14-9.

International Diabetes Federation Epidemiology Task Force Consensus Group. The IDF consensus worldwide definition of the metabolic syndrome. 2005. Available from:

Iwen KA, Schröder E, Brabant G. Thyroid hormones and the metabolic syndrome. Eur Thyroid J. 2013 Jun;2(2):83-92. doi: 10.1159/000351249.

Kapadia KB, Bhatt PA, Shah JS. Association between altered thyroid state and insulin resistance. J Pharmacol Pharmacother. 2012 Apr;3(2):156-60. doi: 10.4103/0976-500X.95517.

Libo Y, Xiaohong L, Feng Y, Wei D, Liu W, Zhang T. Subclinical hypothyroidism and the risk of metabolic syndrome: A meta-analysis of observational studies. Endocr Res. 2016 May;41(2):158-65. doi: 10.3109/07435800.2015.1108332.

Joseph JJ, Golden SH. Cortisol dysregulation: the bidirectional link between stress, depression, and type 2 diabetes mellitus. Ann N Y Acad Sci. 2017 Mar;1391(1):20-34. doi: 10.1111/nyas.13217.

Bhatheja S, Panchal HB, Ventura H, Paul TK. Obesity Cardiomyopathy: Pathophysiologic Factors and Nosologic Reevaluation. Am J Med Sci. 2016 Aug;352(2):219-22. doi: 10.1016/j.amjms.2016.05.014.

Avalon N, Gopal DM, Mooney DM, et al.Preclinical Left Ventricular Diastolic Dysfunction in Metabolic Syndrome. Am J Cardiol. 2014 Sep 15;114(6):838-42. doi: 10.1016/j.amjcard.2014.06.013.

Velarde GP, Sherazi С, Cremer DF, et al. Clinical and Biochemical Markers of Cardiovascular Structure and Function in Women With the Metabolic Syndrome. Am J Cardiol. 2015 Dec 1;116(11):1705-10. doi: 10.1016/j.amjcard.2015.09.010.